Back to results
US 2026/0146241 A1Published application
Engineered CasPhi2 Nucleases
OwnerJ. Keith Joung, Julian Grünewald +3inventors
InventorsJ. Keith Joung, Julian Grünewald, Bret Miller, Eliza Jane Holtz, SeHee Park
Life of this patent
Estimating the term…
Abstract
Described herein are variants of CasPhi2 nucleases with enhanced editing capabilities and methods of use thereof.
Claims56
An isolated CasPhi2 protein, comprising an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% sequence identity to the amino acid sequence of SEQ ID NO:
- 1, and comprising a mutation at one or more of the following positions:
- S11, S25, A36, S106, E107, S124, D134, G138, L149, A156, E159, S160, S164, D167, E168, T203, P233, D337, A261, P277, T355, T357, L370, D427, D428, A435, N497, L506, S507, N508, S509, S511, D513, Q514, T518, P519, A520, P521, G524, A525, K526, K527, P530, V531, E532, V533, R538, T539, E569, L571, S574, E578, S616, T628, T649, D679, Q684, and/or T691.
An isolated CasPhi2 protein, comprising an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% sequence identity to the amino acid sequence of SEQ ID NO:1, and comprising a mutation at one or more of the following positions:
- T355 and/or D679.
Dependencies are inferred from the claim text.